Endocrinology Specialist formulary list
**Other indications for particular drugs may be included on completion of further specialist lists**
The following medicines are approved for prescribing by or on the recommendation of a prescribing diabetes or endocrinology specialist:
| MEDICINE | SUMMARY OF RESTRICTED INDICATION | CATEGORY | PROTOCOL |
| Phenoxybenzamine hydrochloride capsules | Hypertensive episodes in phaeochromocytoma |
 |
Phenoxybenzamine patient information leaflet (PIL) (Tayside Endoweb) |
| Acarbose | Diabetes mellitus when other oral antidiabetic drugs are not tolerated or are contra-indicated |
|
|
| Dapagliflozin▼ in combination with insulin | Type 2 diabetes mellitus in combination with insulin to achieve glycaemic control in patients with eGFR > 60mL/min (see formulary for full restrictions). |
|
|
|
Dapagliflozin and metformin (Xigduo®)▼ in combination with insulin |
Type 2 diabetes mellitus in combination with insulin to achieve glycaemic control in patients with eGFR > 60mL/min (see formulary for full restrictions). |
|
|
| Canagliflozin▼ in combination with insulin | Type 2 diabetes mellitus in combination with insulin to achieve glycaemic control in patients with eGFR > 60mL/min (see formulary for full restrictions). |
|
|
| Pioglitazone in combination with insulin | Type 2 diabetes mellitus in combination with insulin |
|
|
|
Liraglutide
injection (Victoza®▼) (once daily subcutaneous injection) |
Third line for type 2 diabetes mellitus to achieve glycaemic control in patients with eGFR >60mL/min (see formulary for full restrictions). |
|
|
| Lixisenatide injection (Lyxumia®▼) (once daily subcutaneous injection) | Third line for type 2 diabetes mellitus to achieve glycaemic control in patients with eGFR > 30mL/min as second line to liraglutide (see formulary for full restrictions). |
|
Lixisenatide replaces exenatide (existing patients should remain on exenatide). |
| Insulin in combination with liraglutide (unlicensed use ‘off-label’) | In patients with type 2 diabetes either as transition from insulin to liraglutide or combined use of liraglutide with insulin (see protocol for full restrictions). |
|
Local protocol (to be updated) |
| Liothyronine sodium (L-Tri-iodothyronine sodium) tablets | Severe hypothyroid states |
|
Thyroid monitoring advice (Tayside Endoweb) Refer to local Biochemical Medicine Laboratory Handbook for interpretation of results (NHS Tayside Staffnet intranet link only) Liothyronine (Triiodothyronine) PIL (Tayside Endoweb) |
| Liothyronine sodium (L-Tri-iodothyronine sodium) injection | Hypothyroid (myxoedema) coma |
 |
|
| Aqueous Iodine Oral Solution | Thyrotoxicosis (pre-operative) |
|
|
| Fludrocortisone acetate tablets |
Adrenal insufficiency (adjunct therapy) Postural (orthostatic) hypotension (unlicensed use ‘off-label’) |
|
|
| Ulipristal acetate▼ | Pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age |
|
|
| Testosterone enantate injection | Testosterone replacement therapy for male hypogonadism |
|
Hypogonadism PIL (Tayside Endoweb)
Testogel® PIL (Tayside Endoweb) |
| Testosterone undecanoate injection (Nebido®▼) | Testosterone replacement therapy for male hypogonadism |
|
|
| Sustanon 250® injection (testosterone esters: propionate, phenylpropionate, isocaproate, and decanoate) | Testosterone replacement therapy for male hypogonadism |
|
|
| Testosterone undecanoate capsules (Restandol® Testocaps) | Testosterone replacement therapy for male hypogonadism where intramuscular treatment is not suitable |
|
|
| Testosterone gel (Testogel®, Tostran®) | Testosterone replacement therapy for male hypogonadism in those requiring transdermal delivery |
|
|
| Tetracosactide injection (Synacthen®) | Test for adrenocortical function |
|
Standard Short Synacthen test protocol (in electronic booklet from Tayside Endoweb). Refer to local Biochemical Medicine Laboratory Handbook for interpretation of results (NHS Tayside Staffnet intranet link only) |
| Somatropin (Omnitrope®, Saizen®, Norditropin®, Genotropin®) | Adult growth hormone deficiency |
|
Growth Hormones in Adults PIL (Tayside Endoweb) |
| Thyrotropin alfa (rhTSH) (Thyrogen®) | Detection of thyroid remnants & thyroid cancer / increase radio-iodine uptake in post-thyroidectomy patients |
|
|
| Gonadorelin (Gonadotrophin-releasing hormone; GnRH;LH-RH) injection (HRF®) | Assessment of pituitary function |
|
LHRH test protocol (in electronic booklet from Tayside Endoweb) Refer to local Biochemical Medicine Laboratory Handbook for interpretation of results (NHS Tayside Staffnet intranet link only) |
| Desmopressin acetate (nasal spray, tablets, DDAVP® Melt▼) | Diabetes insipidus |
|
|
| Desmopressin acetate 4micrograms/mL injection (DDAVP®) | Diagnosis and treatment of diabetes insipidus |
|
Water deprivation test protocol (in electronic booklet from Tayside Endoweb) |
| Denosumab subcutaneous injection (Prolia®▼) every 6 months |
Postmenopausal
osteoporosis. |
|
Local protocol |
| Zoledronic acid annual intravenous infusion (Aclasta®) |
2nd line option. Postmenopausal osteoporosis in women at increased risk of fractures in patients who are unsuitable for or unable to tolerate oral bisphosphonates. |
|
Tayside MFE Osteoporosis Treatment Algorithm |
| Disodium pamidronate concentrate for intravenous infusion | Paget’s disease of bone |
|
|
| Teriparatide (Forsteo®) |
Severe postmenopausal osteoporosis.
4th line options. |
|
Local protocol |
| Human recombinant parathyroid hormone (Preotact®) |
|
||
|
|
|
|
|
| Metyrapone | Cushing’s syndrome |
|
Metyrapone PIL (Tayside Endoweb) |
| Goserelin (Zoladex® 3.6mg implant) |
Endometriosis,
endometrial thinning prior to ablation or resection, uterine fibroids in
conjunction with iron therapy prior to surgery, pituitary desensitisation
before induction of ovulation by gonadotrophins for in vitro
fertilisation (under specialist supervision) |
|
|
| Octreotide injection, depot injection (Sandostatin LAR®) | Acromegaly; neuroendocrine tumours |
|
Octreotide long acting depot PIL (Tayside Endoweb) Lanreotide PIL (Tayside Endoweb)
Click here
for
Protocol
|
| Lanreotide injection (Somatuline Autogel ®, Somatuline® LA) | Acromegaly; neuroendocrine tumours |
|
| Traffic light status information | |
 |
To be prescribed by Hospital Specialists Only. |
|
|
Can be prescribed in General Practice under the direction of a Specialist. |
